Literature DB >> 28359755

A novel staphylococcal enterotoxin B subunit vaccine candidate elicits protective immune response in a mouse model.

Jun Young Choi1, Sungho Shin2, Na Young Kim3, Woo Sung Son4, Tae Jin Kang5, Dong Hyun Song6, Chi Ho Yu6, Gyeung Haeng Hur6, Seong Tae Jeong6, Young Kee Shin7.   

Abstract

Staphylococcal enterotoxin B (SEB), produced by the gram-positive bacterium Staphylococcus aureus, is responsible for food poisoning and toxic shock syndrome, and is considered a potential bioterrorism agent. Unfortunately, still now no approved vaccines are available against SEB. In this study, we constructed a series of nontoxic SEB mutants (mSEBs) and examined whether these mSEBs provide protective immunity against SEB challenge. These mSEB vaccine candidates did not demonstrate superantigen activity in mouse splenocyte cultures. Immunization with the vaccine candidates triggered the production of IgG-antibodies with neutralizing activity. In addition, increased production of IgG1 and IgG3 was observed after immunization, which signifies both Th1- and Th2-induced immune responses. Among the vaccine candidates tested, S9, a double mutant (N23A and Y90A) and S19, a quadruple mutant (N23A, Y90A, R110A, and F177A), demonstrated complete protection against a lethal SEB challenge. Altogether, our results strongly suggest that these mSEBs could be an effective recombinant SEB vaccine candidates for further/future preclinical and clinical studies.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Mutation; Recombinant vaccine; Staphylococcal enterotoxin B; Vaccine candidates

Mesh:

Substances:

Year:  2017        PMID: 28359755     DOI: 10.1016/j.toxicon.2017.03.012

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  4 in total

1.  Structure of the staphylococcal enterotoxin B vaccine candidate S19 showing eliminated superantigen activity.

Authors:  Woo Hyeon Jeong; Dong Hyun Song; Gyeung Haeng Hur; Seong Tae Jeong
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-10-20       Impact factor: 1.056

Review 2.  Recent advances in Staphylococcus aureus infection: focus on vaccine development.

Authors:  Shamshul Ansari; Rajesh Kumar Jha; Shyam Kumar Mishra; Birendra Raj Tiwari; Ahmed Morad Asaad
Journal:  Infect Drug Resist       Date:  2019-05-13       Impact factor: 4.003

3.  Oral administration of recombinant Bacillus subtilis spores expressing mutant staphylococcal enterotoxin B provides potent protection against lethal enterotoxin challenge.

Authors:  Zhile Xiong; Jialiang Mai; Fei Li; Bingshao Liang; Shuwen Yao; Zhuwei Liang; Chao Zhang; Fei Gao; Xiaolan Ai; Jielin Wang; Yan Long; Min Yang; Sitang Gong; Zhenwen Zhou
Journal:  AMB Express       Date:  2020-12-14       Impact factor: 3.298

4.  SEC is an antiangiogenic virulence factor that promotes Staphylococcus aureus endocarditis independent of superantigen activity.

Authors:  Kyle J Kinney; Sharon S Tang; Xiao-Jun Wu; Phuong M Tran; Nikhila S Bharadwaj; Katherine N Gibson-Corley; Ana N Forsythe; Katarina Kulhankova; Jenny E Gumperz; Wilmara Salgado-Pabón
Journal:  Sci Adv       Date:  2022-05-11       Impact factor: 14.957

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.